| Top 50 Most Viewed Posts Last Week |
|---|
|
Today This Week Last Week This Month Last Month
|
1. KenChowder: Here's what I find important about the new CRC (2172)  (23) |
| 2. KenChowder: My69 wrote: "ESMO, the European Society for (2021) (18) |
| 3. Jake2212: Riz: Great find re CYDY reps listed by ESMO to be (1933) (22) |
| 4. ohm20: I thought I'd better comment before this topic (1895) (23) |
| 5. Rosner: Short Interest Report As of Sat, Aug 3, '13 (1435) |
| 6. Jake2212: Ritz: your point about only 28 mTNBC patients in (1222) (17) |
| 7. MGK_2: ohm, based on the overall survivability you've (852) (5) |
| 8. Riztheinvestor: ESMO calendar was this interesting tidbit. (840) (17) |
| 9. My69z: Look @ this FDA accelerated approval days ago: (833) (18) |
| 10. ohm20: There seems to be a couple of mistakes in that (796) (24) |
| 11. Mr3Putt: Abstract for Dr. P: Presentation Number 369P (768) (18) |
| 12. My69z: Dr. Ari D. Baron @ BGT's colorectal poster find: (752) (7) |
| 13. misiu143: Great post from IHUB.. easy explanation to many (738) (26) |
| 14. Riztheinvestor: Does anything think accelerated approval is a (728) (9) |
| 15. Riztheinvestor: https://cslide.ctimeetingtech.com/gi2025/attendee (718) (19) |
| 16. Jake2212: The intriguing implications of hiring a new CFO (715) (25) |
| 17. ohm20: "In other words...Leronlimab is at LEAST 25 times (713) (13) |
| 18. ohm20: Do we think that Leronlimab is a time saving (698) (38) |
| 19. ohm20: CytoDyn Leadership Team To Attend ESMO Breast (690) (36) |
| 20. biloxiblues: ohm20 Great answers as usual, so I asked my (688) (11) |
| 21. Riztheinvestor: We should be at .80 before any news. If something (677) (16) |
| 22. Mr3Putt: should have included this info on abstract (676) (9) |
| 23. ohm20: What do we think about the low mOS? Is it still a (674) (15) |
| 24. grow: I don't know if this is useful to you in your (671) (10) |
| 25. ScottyDoggs: The latest data on TNBC, and CRC must have been (658) (16) |
| 26. TechGuru: Sjacobs26, In preparation for the ESMO results (650) (18) |
| 27. mikeyt1818: Seems like the grants keep them afloat until they (644) (4) |
| 28. KenChowder: Here's the abstract from the Munich conference: (643) (8) |
| 29. ohm20: Only 3 of the 28 patients had the optimal 700 mg (632) (8) |
| 30. My69z: From our new CFO profile CombiMatrix. It merged (621) (4) |
| 31. Jake2212: I just heard from Mightycydy, one of our (619) (24) |
| 32. ohm20: One of the problems with AI is that it narrowly (617) (26) |
| 33. ohm20: So we have this promising data. Perhaps (605) (6) |
| 34. MidnightRider: 10 billion equates to roughly 8.30 per (603) (12) |
| 35. brentie: From stocktwits FDA: "We're looking at (601) (10) |
| 36. jeff67: I was in hi tech for 40 years. This is the way (597) (15) |
| 37. ohm20: Is Gilead hoping that Merck would want to combine (595) (21) |
| 38. My69z: Dr. Rui holds the position of Professor of Cancer (593) (5) |
| 39. Katangolo: Smells like MD Anderson (591) (5) |
| 40. ohm20: A mea culpa I should stop posting when I've been (591) (5) |
| 41. MJS719: From Reddit Post It looks like CytoDyn has hired (589) (14) |
| 42. ohm20: And good luck to you I don't need luck, I'm (587) (31) |
| 43. KenChowder: So the statistical takeaway as I see it is in (586) (14) |
| 44. mountaineer: If this turns out to be correct, (586) (17) |
| 45. MGK_2: 55:22: So when we look again at their tumor (584) (12) |
| 46. Jake2212: Riz: Another great find. As you point out, this (582) (21) |
| 47. ohm20: Now to say the complete opposite (that LL (581) (17) |
| 48. Evil Rabbit: I would imagine we’ll be green tomorrow if the (577) (6) |
| 49. sjacobs26: Wouldn't being 3rd and 4th line of treatment (575) (11) |
| 50. Riztheinvestor: I’m also thinking we have a Late Break (573) (3) |
